{"id":"aclarubicin","rwe":[],"tags":[{"label":"aclarubicin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 2B","category":"target"},{"label":"HTR2B","category":"gene"},{"label":"MMP2","category":"gene"},{"label":"TOP1","category":"gene"},{"label":"L01DB04","category":"atc"},{"label":"Active","category":"status"},{"label":"Acute myeloid leukemia, disease","category":"indication"},{"label":"Adjuvants, Immunologic","category":"pharmacology"},{"label":"Antibiotics, Antineoplastic","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Immunologic Factors","category":"pharmacology"},{"label":"Topoisomerase II Inhibitors","category":"pharmacology"},{"label":"Topoisomerase Inhibitors","category":"pharmacology"}],"phase":"phase_3","safety":{"safetySignals":[{"llr":313.186,"date":"","count":75,"signal":"Bone marrow failure","source":"DrugCentral FAERS","actionTaken":"Reported 75 times (LLR=313)"},{"llr":106.286,"date":"","count":30,"signal":"Myelosuppression","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=106)"}],"commonSideEffects":[{"effect":"Bone marrow failure","drugRate":"LLR 313","severity":"common"},{"effect":"Myelosuppression","drugRate":"LLR 106","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"aclacur","offLabel":[],"synonyms":["aclacinomycin","Aclacinomycin A","aclacur","aclarubicin","Antibiotic 3082A","aclarubicin hydrochloride","aclarubicin HCl"],"timeline":[],"brandName":"Aclacur","ecosystem":[{"indication":"Acute myeloid leukemia, disease","otherDrugs":[{"name":"aldesleukin","slug":"aldesleukin","company":"Chiron"},{"name":"azacitidine","slug":"azacitidine","company":"Celgene"},{"name":"cytarabine","slug":"cytarabine","company":""},{"name":"daunorubicin","slug":"daunorubicin","company":""}],"globalPrevalence":800000}],"mechanism":{"target":"5-hydroxytryptamine receptor 2B","targets":[{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"MMP2","source":"DrugCentral","target":"72 kDa type IV collagenase","protein":"72 kDa type IV collagenase"},{"gene":"TOP1","source":"DrugCentral","target":"DNA topoisomerase 1","protein":"DNA topoisomerase 1"},{"gene":"TOP2A","source":"DrugCentral","target":"DNA topoisomerase II","protein":"DNA topoisomerase 2-alpha"},{"gene":"TOP2B","source":"DrugCentral","target":"DNA topoisomerase II","protein":"DNA topoisomerase 2-beta"}],"modality":"Small Molecule","drugClass":"aclarubicin","explanation":"Imagine your cells are like a city, and the 5-hydroxytryptamine receptor 2B is like a traffic light that helps control how fast the city grows. Aclacur is like a traffic cop that blocks the traffic light, slowing down the growth of cancer cells. This helps to stop the cancer from spreading.","oneSentence":"Aclacur works by binding to the 5-hydroxytryptamine receptor 2B, which is involved in cell growth and proliferation.","technicalDetail":"Aclacur exerts its effects by competitively binding to the 5-hydroxytryptamine receptor 2B, which is a G-protein coupled receptor involved in the regulation of cell growth and proliferation. This binding event triggers a cascade of downstream effects that ultimately lead to the inhibition of cancer cell growth and induction of apoptosis."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/80","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ACLARUBICIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACLARUBICIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:25:26.769003","biosimilars":[],"competitors":[{"drugName":"doxorubicin","drugSlug":"doxorubicin","fdaApproval":"1974-08-07","genericCount":24,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"daunorubicin","drugSlug":"daunorubicin","fdaApproval":"1979-12-19","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"epirubicin","drugSlug":"epirubicin","fdaApproval":"1999-09-15","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"idarubicin","drugSlug":"idarubicin","fdaApproval":"1990-09-27","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mitoxantrone","drugSlug":"mitoxantrone","fdaApproval":"1987-12-23","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"valrubicin","drugSlug":"valrubicin","fdaApproval":"1998-09-25","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"aclarubicin","indications":{"approved":[{"name":"Acute myeloid leukemia, disease","source":"DrugCentral","snomedId":91861009,"regulator":"FDA","usPrevalence":null,"globalPrevalence":800000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency 2018[INST])"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"doxorubicin","brandName":"doxorubicin","genericName":"doxorubicin","approvalYear":"1974","relationship":"same-class"},{"drugId":"daunorubicin","brandName":"daunorubicin","genericName":"daunorubicin","approvalYear":"1979","relationship":"same-class"},{"drugId":"epirubicin","brandName":"epirubicin","genericName":"epirubicin","approvalYear":"1999","relationship":"same-class"},{"drugId":"idarubicin","brandName":"idarubicin","genericName":"idarubicin","approvalYear":"1990","relationship":"same-class"},{"drugId":"mitoxantrone","brandName":"mitoxantrone","genericName":"mitoxantrone","approvalYear":"1987","relationship":"same-class"},{"drugId":"valrubicin","brandName":"valrubicin","genericName":"valrubicin","approvalYear":"1998","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07486726","phase":"PHASE1,PHASE2","title":"Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2026-03-15","conditions":["Acute Myeloid Leukemia (AML)","Relapse Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia (AML)"],"enrollment":112,"completionDate":"2028-10"},{"nctId":"NCT06928376","phase":"PHASE2","title":"A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-04-18","conditions":["Acute Myeloid Leukemia","First Line Therapy"],"enrollment":160,"completionDate":"2026-09-01"},{"nctId":"NCT07319793","phase":"NA","title":"Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-01-01","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes (MDS)"],"enrollment":200,"completionDate":"2028-06-30"},{"nctId":"NCT05662956","phase":"PHASE2","title":"A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients","status":"COMPLETED","sponsor":"Hematology department of the 920th hospital","startDate":"2022-12-01","conditions":["Acute Myeloid Leukemia"],"enrollment":114,"completionDate":"2025-04-30"},{"nctId":"NCT06394011","phase":"PHASE2","title":"Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-02-15","conditions":["Intermediate Risk Acute Myeloid Leukemia","High Risk Acute Myeloid Leukemia"],"enrollment":60,"completionDate":"2026-12-30"},{"nctId":"NCT05893472","phase":"PHASE1,PHASE2","title":"A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML.","status":"UNKNOWN","sponsor":"ZePing Zhou","startDate":"2023-04-01","conditions":["Acute Myeloid Leukemia","Venetoclax"],"enrollment":45,"completionDate":"2024-04-01"},{"nctId":"NCT05264883","phase":"PHASE3","title":"Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-03-01","conditions":["Acute Myeloid Leukemia"],"enrollment":170,"completionDate":"2025-02-28"},{"nctId":"NCT05382390","phase":"PHASE3","title":"Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Huihan Wang","startDate":"2022-01-21","conditions":["Acute Myeloid Leukemia"],"enrollment":130,"completionDate":"2026-01-21"},{"nctId":"NCT05258799","phase":"NA","title":"Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study","status":"UNKNOWN","sponsor":"Huihan Wang","startDate":"2022-01-21","conditions":["Acute Myeloid Leukemia"],"enrollment":130,"completionDate":"2026-01-21"},{"nctId":"NCT04716114","phase":"PHASE3","title":"A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-03-24","conditions":["Acute Myeloid Leukemia (AML)"],"enrollment":315,"completionDate":"2025-12"},{"nctId":"NCT04254640","phase":"PHASE2","title":"Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-03-01","conditions":["Acute Myeloid Leukemia","Elderly Patients","Newly Diagnosed"],"enrollment":34,"completionDate":"2023-12-31"},{"nctId":"NCT02723448","phase":"PHASE1","title":"Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-12-05","conditions":["Vasculopathy, Retinal, With Cerebral Leukodystrophy","Cerebroretinal Vasculopathy, Hereditary"],"enrollment":4,"completionDate":"2020-07-23"},{"nctId":"NCT04446130","phase":"PHASE3","title":"Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-01-01","conditions":["Induction Chemotherapy","Acute T-Lymphocytic Leukemia","T-cell Lymphoblastic Lymphoma Leukemia","T-cell/Myeloid Mixed Phenotype Acute Leukemia"],"enrollment":100,"completionDate":"2024-01-01"},{"nctId":"NCT04216355","phase":"PHASE2,PHASE3","title":"Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2020-01","conditions":["MDS-EB"],"enrollment":20,"completionDate":"2023-12"},{"nctId":"NCT04168138","phase":"NA","title":"D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients","status":"UNKNOWN","sponsor":"Huihan Wang","startDate":"2019-11-01","conditions":["Acute Myeloid Leukemia"],"enrollment":20,"completionDate":"2024-12-30"},{"nctId":"NCT04087967","phase":"PHASE3","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-04-01","conditions":["Acute Myeloid Leukemia","Induction Chemotherapy"],"enrollment":162,"completionDate":"2022-05-31"},{"nctId":"NCT04083911","phase":"PHASE3","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-04-01","conditions":["Acute Myeloid Leukemia","Induction Chemotherapy"],"enrollment":50,"completionDate":"2022-05-31"},{"nctId":"NCT03181815","phase":"PHASE2","title":"Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-01-01","conditions":["Acute Myeloid Leukemia","Relapse Leukemia"],"enrollment":48,"completionDate":"2019-12-31"},{"nctId":"NCT02886559","phase":"PHASE1,PHASE2","title":"Chidamide Plus DCAG for Relapsed/Refractory AML","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2016-06","conditions":["AML","Relapse"],"enrollment":100,"completionDate":"2019-06"},{"nctId":"NCT03045627","phase":"PHASE2","title":"Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2017-01","conditions":["Acute Myeloid Leukemia"],"enrollment":120,"completionDate":"2020-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000168464","NDDF":"003919","UNII":"74KXF8I502","CHEBI":"CHEBI:74619","INN_ID":"4945","RXNORM":"239","UMLSCUI":"C0001143","ChEMBL_ID":"CHEMBL502620","KEGG_DRUG":"D01911","DRUGBANK_ID":"DB11617","PUBCHEM_CID":"451415","SNOMEDCT_US":"326830005","SECONDARY_CAS_RN":"75443-99-1","MESH_DESCRIPTOR_UI":"D015250","MESH_SUPPLEMENTAL_RECORD_UI":"C011157"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":540,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01DB04","allCodes":["L01DB04"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aclacur, also known as aclarubicin, is a small molecule drug that targets the 5-hydroxytryptamine receptor 2B. It is used to treat acute myeloid leukemia. The commercial status of Aclacur is unknown, and it is not clear if it is patented or available as a generic. Aclacur's safety considerations are also unknown. Further research is needed to fully understand its pharmacological properties.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}